3,4-Dimethoxyamphetamine
3,4-Dimethoxyamphetamine, or simply dimethoxyamphetamine, is a psychedelic drug of the phenethylamine and amphetamine families. It is one of the dimethoxyamphetamine series of positional isomers.
The drug has been assessed in various biochemical and preclinical studies. It has been tried in humans at doses of up to 700mg intravenously, with mescaline-like effects reported. 3,4-DMA is also orally active and has produced sympathomimetic effects at a dose of 160mg. Its duration is unknown.
Its affinity for the rat serotonin 5-HT2A receptor has been assessed and was found to be 43,300nM. For comparison, the affinity of para-methoxyamphetamine was 33,600nM, of 2,5-dimethoxyamphetamine was 5,200nM, and of 2,5-dimethoxy-4-methylamphetamine was 100nM in the same study. 3,4-DMA also showed affinity for the 5-HT1 receptor. The drug has additionally been found to be a monoamine oxidase inhibitor, with an of 20,000nM for monoamine oxidase A, whereas it was inactive at monoamine oxidase B .
3,4-DMA fails to produce stimulus generalization to dextroamphetamine in rodent drug discrimination tests, suggesting that it lacks psychostimulant- or amphetamine-like effects.
3,4-DMA produces 3-methoxy-4-hydroxyamphetamine as its major metabolite in dogs and monkeys.
The drug is a controlled substance in Canada under amphetamine blanket-ban language. It is not an explicitly controlled substance in the United States, but may be considered scheduled as an isomer of 2,5-dimethoxyamphetamine.